A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Summary

The purpose of CTO-IUSCC-0730 study is to assess the clinical efficacy of LY3214996 in combination with abemaciclib at the recommended phase 2 dose of LY3214996 200 mg orally daily and abemaciclib 150 mg orally twice daily. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.

Timeline

Start

2020-10-05

Primary completion

2023-08-07

Completion

2023-08-07

Drugs

Indications